Scientific Program

OPENING OPENING SESSION
08:30-09:00 Opening speeches
SESSION 1 Turkish Microbiology Society Session
Chairs Dr. Mustafa Özyurt (Turkey), Dr. Peter Konturek (Germany)
09:00-09:20 What? A potential diagnostic tool? A stratification tool? A target for modulation? A source of new drugs?
Dr. Herve Blottiere, INRA, France
09:20-09:40 Microbiome as a data-oriented science and the translation of AI technologies to omics tools
Dr. Ufuk Nalbantoğlu, Erciyes University, Turkey
09:40-10:00 How an evidence based research related to microbiota should be designed?
Dr. Yakut Akyön Yılmaz, Hacettepe University, Turkey
10:00-10:20 Towards Turkish Microbiome Project
Dr. Aycan Gündoğdu, Erciyes University, Turkey
10:20-10:30 Discussion
10:30-11:00 Coffee Break
SESSION 2 HOT TOPICS IN MICROBIOTA
Chairs Dr. Adil Mardinoğlu (Turkey), Dr. Thorh Haahr (Denmark)
11:00 -11:20

Hot topics in gut microbiota
Dr. Lena Ohman, University of Gothenburg, Sweden

11:20 -11:40

Probiotics in prevention and management of GDM
Dr. Kirsi Laitinen, University of Turku, Finland

11:40 -12:00

The fungal microbiome and its interaction with gut bacteria in the host
Dr. In Young Hwang, National University of Singapure, Singapure

12:00 -12:20

The short chain fatty acids revival – Key physiological role of bacterial metabolites for the gut and for the whole body.
Dr. Herve Blottiere, INRA, France

12:20 -12:30 Discussion
SESSION 3 ZYMO RESEARCH EUROPE GmbH SESSION
Chairs Dr. Osman Uğur Sezerman, Acibadem University, Turkey
12:30 - 12:50

Improving the Accuracy and Reproducibility of Microbiome Measurements Across Labs
Dr. Thomas Kuri, Zymo Research Europe GmbH, Germany

12:50 -13:00 Discussion
13:00 -14:00 Lunch
SESSION 4 GUT MICROBIOTA I
Chairs Dr. Süleyman Yıldırım (Turkey) ,Dr. Sahar El Aidy (The Netherland)
14:00-14:20

Systems Biology of Host-Microbiome Interactions; From Associations to Causality
Dr. Saeed Shoaie, King’s College London, UK

14:20-14:40

Overall Dietary Quality Relates to Gut Microbiota Diversity and Abundance
Dr. Kirsi Laitinen, University of Turku, Finland

14:40-15:00

Reprogrammable microbial cell-based therapeutics against antibiotic-resistant bacteria.
Dr. In Young Hwang, National University of Singapure, Singapure

15:00-15:20

The intestinal microbiota composition and weight development in children: the KOALA Birth Cohort Study
Dr. John Penders, Maastricht University, The Netherlands.

15:20-15:30 Discussion
15:30-16:00 Coffee Break
SESSION 5 GUT MICROBIOTA II
Chairs Dr. Kirsi Laitinen (Finland),  Dr. Ömer Faruk Beşer (Turkey)
16:00-16:20

İmpact of antimicrobial therapy on the gut microbiota
Dr. W.J. Wiersinga, University of Amsterdam, Netherland

16:20-16:40

The microbial pharmacy within us;  role of gut bacterial metabolic activity in the gut-brain homeostasis 
Dr. Sahar El Aidy, University of Groningen, The Netherlands

16:40-17:00

Role of the gut microbiota in liver diseases
Dr. Philippe Gerard, INRA, Micalis Institute, France

17:00-17:20

The role of gut microbiota in sepsis
Dr. W.J. Wiersinga, University of Amsterdam, The Netherland

17:00-17:30 Discussion
SESSION 6 MICROBIOTA AND CANCER
Chairs Dr. Herve Blottiere (France), Dr. Yakut Akyön Yılmaz (Turkey)
17:30-17:50

ILC-microbiota cross-talk in lung cancer
Dr. Fay Magnusson, İstanbul Medipol University, Turkey

17:50-18:20

Microbiota and colon cancer
Dr. Taylan Kav, Hacettepe University, Turkey

18:20-18:40

HPV infections and cancer
Dr. Ferit Saraçoglu, YİSAV , Turkey

18:40-18:50 Discussion
SESSION 7 MICROBIOTA AND GASTROINTESTINAL SYSTEM
Chairs  Dr. In Young Hwang (Singapure),  Dr. Muazzes Garipağaoğlu (Turkey)
09:00-09:20 Microbiota in patients with inflammatory bowel disease.
Dr. Lena Ohman, University of Gothenburg, Sweden
09:20-09:40 Does our microbiome travel well: the role of international travel on the gut microbiome and resistome.
Dr. John Penders, Maastricht University, The Netherlands.
09:40-10:00 Liver and microbiota, there is more and more evidence that dysbiosis is an important driving force 
Dr. Peter Konturek , University of Jena ,Germany
10:00-10:20 Functional Metagenomics as a powerful approach for drug discovery
Dr. Herve Blottiere, INRA, France
10:20-10:30 Discussion
10:30-11:00 Coffee Break
SESSION 8 GUT MICROBIOTA III
Chairs  Dr. Cumhur Özkuyumcu (Turkey), Dr. Sercan Karav (Turkey)
11:00 -11:20

The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies.
Dr. Maria Jenmalm, Linkoping  University, Sweden

11:20 -11:40

The progress in fecal microbiota therapy
Dr. Peter Konturek ,  University of Jena ,Germany

11:40 -12:00

Metabolism of cholesterol and bile acids by the gut microbiota
Dr. Philippe Gerard,  INRA, Micalis Institute, France

12:00 -12:20

Gut and Energy homeostasis
Dr. Gilles Mithieux, University of Lyon,France

12:20 -12:30 Discussion
SESSION 9 ORAL PRESENTATİON 
Chairs Dr. Aycan Gündoğdu (Turkey), Dr. Fay Magnusson (Turkey)
12:30 - 12:40

OP-001 Use of Human Microbiome Associated Novel Enzymes to Understand How Lactoferrin Shapes Our Gut Microbiome
Sercan Karav

12:40-12:50 OP-003 The effect of diet on microbiota diversity and composition investigated on a large cohort
Mehmet Hora  
12:50-13:00 OP-004 Molecular Genetic Differences Of High And Low Level Isoniazid Resistance In Multi Drug Mycobacterium Tuberculosis 
Khaoula Balgouthi
13:00 -14:00

Lunch

SESSION 10 MICROBIOTA AND IMMUN SYSTEM
Chairs Dr. Philippe Gerard (France), Dr. Bahar Eren Kuru (Turkey)
14:00-14:20

Development of microbiota and immune system in infants
Dr. Hasan Özen, Hacettepe University, Turkey

14:20-14:40

The role of the oral microbiota in immune and allergy development
Dr. Maria Jenmalm, Linkoping  University, Sweden

14:40-15:00

Effect of microbiota on vaccination
Dr. Cumhur Özkuyumcu, Hacettepe University, Turkey

15:00-15:10 Discussion
15:10-15:30 Coffee Break
SESSION 11 MICROBIOTA AND NEUROPSYCHIATRY
Chairs Dr. John Penders (The Netherlands), Dr. Taylan Kav (Turkey)
15:30-15:50

Gut Brain Axis
Dr. Gilles Mithieux, University of Lyon, France

15:50-16:10

Multi-class Classification of Dementia in Parkinson’s Disease Using Microbiota, Neuroimaging, and Clinical Scores.
Dr. Süleyman Yıldırım, İstanbul Medipol University, Turkey

16:10-16:30

A profound metabolic reorientation in the intestinal mucosa upon microbial colonization
Dr. Sahar El Aidy, University of Groningen, The Netherlands

16:30-16:40 Discussion
SESSION 12 ORAL PRESENTATİON 
Chairs Dr. Süleyman Yıldırım (Türkiye), Dr. Funda Elmacıoğlu (Türkiye)
16:40-16:50

OP-005 Current applications and challanges of Microfluidics-based and Single-cell Metagenomics  
Ali Yavuz Çakır

16:50-17:00

OP-006 Comparison of Oral and Nasal Microbiota in Parkinson’s Disease Patients at Different Cognitive States

Dr. Muzaffer Arikan

17:00-17:10

OP-015 Knowledge and Consumption Habits of Probiotics of Medical Faculty Students' in Turkey  
Kevser Atalık

17:10-17:20 OP-016 Two-way benefits of potential prebiotic polyphenols and gut microbiota
Eda Nur Ayar
SESSION 13 MICROBIOTA AND METABOLISM I
Chairs Dr. W.Joost Wiersinga (The Netherland), Dr. Maria Jenmalm (Sweden) 
17:20-17:40

Gut microbiota and host metabolism
Dr. Gilles Mithieux, University of Lyon, France

17:40-18:00

The role of Gut Microbiota in Obesity and type 2 and type 1 Diabetes Mellitus: New insights  into “old” disease. 
Dr. Peter Konturek, University of Jena, Germany

18:00-18:20

Oral microbiota. 
Dr. Bahar Eren Kuru, Yeditepe University Dental School & Hospital, Turkey 

18:20-18:40 Human gut microbiota and the polyamines
Dr. Nihal Büyükuslu, İstanbul Medipol University, Turkey
18:40-18:50 Discussion
SESSION 14 MICROBIOTA AND METABOLISM II
Chairs Dr. Gülgün Ersoy (Turkey), Dr. Lena Ohman (Sweden)
09:00-09:20 Multiomics appoaches for Understanding the Clycocompotence of Human Gut Microbiome 
Dr. Sercan Karav, Çanakkale Onsekiz Mart University, Turkey
09:20-09:40 Gut microbiota and PCOS
Dr. Okan Bülent Yıldız, Hacettepe University, Turkey
09:40-09:50 OP-019  Gut Mıcrobıota And Carcınogenesıs
Mustafa Güzel      
09:50-10:00 OP-017 Electron Transport System  in Bifidobacterium animalis subspecies lactis BB-12  Hüseyin Sancar Bozkurt
10:00-10:10 Discussion
10:10-10:30 Coffee Break
SESSION 15 MICROBIOTA MANIPULATION
Chairs Dr. Shirin Moossavi (Canada), Dr. Fay Magnusson (Turkey)
10:30-10:50

Targeted approaches for in situ gut microbiome manipulation.
Dr. In Young Hwang, National University of Singapure, Singapure.

10:50-11:10

Probiotics use in gastroenteritis 
Dr. Hasan Özen, Hacettepe University, Turkey

11:10-11:30

Engineering microbes for targeted strikes against human pathogenes
Dr. In Young Hwang, National University of Singapure, Singapure.

11:30-11:40 Discussion
SESSION 16 ORAL PRESENTATİON 
Chairs Dr. Hasan Özen (Turkey),  Dr. Sertaç Arslanoğlu (Turkey)
11:40-11:50

OP-007 Investigation Of Retrospective Closridium Difficile And Evaluation Of Epidemiological Properties In Patients With Diagnosis        
Merve Ayyıldız

11:50-12:00 OP-008  Metagenome-wide association studies of human gut metagenome reveals genetic variations associated with liver cirrhosis 
Kübra Yalçın
12:00-12:10 OP-009 Gut microbiota and oral contraceptive use on in polycystic ovary syndrome
Damla Eyüpoğlu
12:10-12:20 OP-010 Comparison of the Gut Microbiota in Turkish Patients with Irritable Bowel Syndrome and Healthy Controls using Next Generation Sequencing: Roles of Eating Habits and Protozoa in the Gut    
Özgür Kurt
12:20-12:30 OP-011 Fecal Microbiota Transplantation Effect on Obesity Treatment: An Experimental Study
Fatma Zehra Yaşar
12:30-12:40 OP-012 Investigation of the Relationship Between Rosacea and Chronic Spontaneous Urticaria and Gut Microbioma 
Elif  Özözen
12:40-12:50 OP-014 The association of Alzheimer’s disease and structural genetic variations in certain strains of gut microbiome
Ayşenur Soytürk
12:50-13:00 OP-020 Effects of traditional fermented foods on pregnant women with idiopathic granulomatous mastitis (IGM) complicated with erythema nodosum (EN)   
Mavise Yüksel 
13:00-14:00 Lunch
SESSION 17 NEONATES' MICROBIOTA
Chairs Dr. Gilles Mithieux (France), Dr. Ferit Saraçoğlu (Turkey)
14:00-14:20

The role of the mode of delivery in microbiota development
Dr. Maria Jenmalm, Linkoping  University, Sweden

14:20-14:40

The use of system biology in treatment of liver diseases
Dr. Adil Mardinoğlu , King's College London, Turkey

14:40-15:00

Vaginal seeding or vaginal microbial transfer from the mother to the caesarean-born neonate
Dr. Thor Haahr, Aarhus University, Denmark 

15:00-15:10 Discussion
15:10-15:30 Coffee Break
SESSION 18 MICROBIOTA AND PREGNANCY
Chairs Dr. Aycan Gündoğdu (Turkey), Dr. Ufuk Nalbantoğlu (Turkey)
15:30-15:50

The prebiotic and probiotic prepentions of human milk immune develeopment of the infant.
Dr. Shirin Moossavi, University of Manitoba, Canada

15:50-16:10

Microbiota and Fetal Programming
Dr. Ferit Saracoglu, YİSAV, Turkey

16:10-16:30

Vaginal Microbiota and İVF outcomes
Dr. Thor Haahr, Aarhus University, Denmark 

16:30-16:40 Discussion
SESSİON 19 ORAL PRESENTATİON 
Chairs Dr. Taylan Kav (Turkey), Dr. Okan Bülent Yıldız (Turkey)
16:40-16:50

OP-021 Determination of Olive and Apple Vinegar Microbiota by Polymerase Chain Reaction-Denaturing Gradient Gel Electrophoresis (PCR-DGGE) Method
Burcu Oktay

16:50-17:00

OP-022 Presence Of Vancomycın Resıstant  Enterococcus Infectıon  In Enterococcus Carrıers (Vre)  
Naciye Badır

17:00-17:10

OP-023  Evaluation of intestinal microbiota in children with sickle cell diseases
Serap SÜZÜK YILDIZ

17:10-17:20 OP-024 Autism with the perspective of microbiota gut brain axis   
Recep Keşli
17:20-17:30 OP-025 Virulence factors of pathogens in microbiota and their relation with diseases      
Sinem Öktem Okullu
17:30 Closing Ceremony